Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients.
Marianna Nuti(National Institutes of Health), Paolo Marchetti(Sapienza University of Rome), Chiara Napoletano(Sapienza University of Rome), Andrea Botticelli(Sapienza University of Rome), Ilary Ruscito(Sapienza University of Rome), Concetta Elisa Onesti, Ilaria Grazia Zizzari(Sapienza University of Rome), Aurelia Rughetti(Sapienza University of Rome), Hassan Rahimi(Sapienza University of Rome), Alain Gelibter(Policlinico Umberto I), Alessio Ugolini(The Wistar Institute), Federica Mazzuca, Enrico Cortesi(Sapienza University of Rome), Fabio Calabrò(Carlo Forlanini Hospital)
Cited by 5
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
A spectrum of monoclonal antibodies reactive with human mammary tumor cells.
|Proceedings of the National Academy of Sciences|1981|563
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
|British Journal of Cancer|2020|350
A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor‐associated antigen in human mammary carcinoma cell populations
|International Journal of Cancer|1982|327